MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary

percutaneous coronary intervention [PCI]) and the ionising radiation connected to PCI. Both the TTFM and HFUS probes can be used on multiple patients after cleaning and sterilisation. There is no published evidence to support these claims. Recent and ongoing studies Flow distribution in arterial composite grafts in patients with coronary heart disease undergoing coronary artery bypass grafting. ACTRN12622000774729. Status: not yet recruiting. Indication: coronary heart disease leading to coronary artery bypass grafting. Devices: MiraQ TTFM and HFUS. Estimated completion date: not reported. Country: Czech Republic. Expert comments Comments on this technology were invited from clinical experts working in the field and relevant patient organisations. The comments received are individual opinions and do not represent NICE's view. Two out of 3 experts were familiar with or had used this technology before. Level of innovation Two clinical experts commented that the technology has been around for some time, about 20 years. One expert said that other modalities offer the same information but at no extra cost and 1 expert said that MiraQ cardiac is the most user-friendly form that this technology has been presented in. The other expert said that MiraQ cardiac is a useful tool for quality control of anastomotic issues.
